These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 24139833

  • 1. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness.
    Koumaras C, Tziomalos K, Stavrinou E, Katsiki N, Athyros VG, Mikhailidis DP, Karagiannis A.
    J Am Soc Hypertens; 2014 Feb; 8(2):74-82. PubMed ID: 24139833
    [Abstract] [Full Text] [Related]

  • 2. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB.
    J Am Soc Hypertens; 2012 Feb; 6(5):338-45. PubMed ID: 22995802
    [Abstract] [Full Text] [Related]

  • 3. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, Keefe DL.
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [Abstract] [Full Text] [Related]

  • 4. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.
    Mahmud A, Feely J.
    Am J Hypertens; 2008 Jun; 21(6):663-7. PubMed ID: 18437130
    [Abstract] [Full Text] [Related]

  • 5. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
    Polónia J, Barbosa L, Silva JA, Bertoquini S.
    Blood Press Monit; 2010 Oct; 15(5):235-9. PubMed ID: 20577082
    [Abstract] [Full Text] [Related]

  • 6. Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients.
    Virdis A, Ghiadoni L, Qasem AA, Lorenzini G, Duranti E, Cartoni G, Bruno RM, Bernini G, Taddei S.
    Eur Heart J; 2012 Jun; 33(12):1530-8. PubMed ID: 22450428
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS.
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [Abstract] [Full Text] [Related]

  • 8. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
    McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J, Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators.
    Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials.
    Shahin Y, Khan JA, Chetter I.
    Atherosclerosis; 2012 Mar; 221(1):18-33. PubMed ID: 22209214
    [Abstract] [Full Text] [Related]

  • 10. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol.
    Hwang JW, Kim EK, Jang SY, Chung TY, Ki CS, Sung K, Kim SM, Ahn J, Carriere K, Choe YH, Chang SA, Kim DK.
    Rev Esp Cardiol (Engl Ed); 2018 Sep; 71(9):743-749. PubMed ID: 29198406
    [Abstract] [Full Text] [Related]

  • 12. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study.
    Vitale C, Marazzi G, Iellamo F, Spoletini I, Dall'Armi V, Fini M, Volterrani M.
    Int J Cardiol; 2012 Mar 08; 155(2):279-84. PubMed ID: 22078979
    [Abstract] [Full Text] [Related]

  • 13. Effect of lisinopril and atenolol on aortic stiffness in patients on hemodialysis.
    Georgianos PI, Agarwal R.
    Clin J Am Soc Nephrol; 2015 Apr 07; 10(4):639-45. PubMed ID: 25784174
    [Abstract] [Full Text] [Related]

  • 14. Effect of aliskiren on circulating endothelial progenitor cells and vascular function in patients with type 2 diabetes and essential hypertension.
    Raptis AE, Markakis KP, Mazioti MC, Ikonomidis I, Maratou EP, Vlahakos DV, Kotsifaki EE, Voumvourakis AN, Tsirogianni AG, Lambadiari VA, Lekakis JP, Raptis SA, Dimitriadis GD.
    Am J Hypertens; 2015 Jan 07; 28(1):22-9. PubMed ID: 24994608
    [Abstract] [Full Text] [Related]

  • 15. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M, Simioni N, Masiero A.
    Minerva Endocrinol; 2009 Dec 07; 34(4):333-8. PubMed ID: 20046162
    [Abstract] [Full Text] [Related]

  • 16. Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension.
    Guo JQ, Wang HY, Sun NL.
    Chin Med J (Engl); 2013 Apr 07; 126(7):1242-6. PubMed ID: 23557551
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of nebivolol and metoprolol on arterial stiffness, circulating progenitor cells, and oxidative stress.
    Hayek SS, Poole JC, Neuman R, Morris AA, Khayata M, Kavtaradze N, Topel ML, Binongo JG, Li Q, Jones DP, Waller EK, Quyyumi AA.
    J Am Soc Hypertens; 2015 Mar 07; 9(3):206-13. PubMed ID: 25681236
    [Abstract] [Full Text] [Related]

  • 18. A meta-analysis of randomized controlled trials assessing the impact of beta-blockers on arterial stiffness, peripheral blood pressure and heart rate.
    Niu W, Qi Y.
    Int J Cardiol; 2016 Sep 01; 218():109-117. PubMed ID: 27232921
    [Abstract] [Full Text] [Related]

  • 19. The renin-angiotensin-aldosterone system blockade and arterial stiffness in renal transplant recipients - a cross-sectional prospective observational clinical study.
    Heleniak Z, Illersperger S, Brakemeier S, Bach P, Dębska-Ślizień A, Budde K, Halleck F.
    Acta Biochim Pol; 2020 Dec 17; 67(4):613-622. PubMed ID: 33332078
    [Abstract] [Full Text] [Related]

  • 20. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K.
    Vnitr Lek; 2010 Feb 17; 56(2):120-6. PubMed ID: 20329582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.